Analyst Research

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc announces FDA approves RAGWITEK Sublingual tablet as immunotherapy to treat short ragweed Pollen-Induced Allergic Rhinitis with or without conjunctivitis in adults


Thursday, 17 Apr 2014 06:22pm EDT 

Merck & Co Inc:U.S. Food and Drug Administration (FDA) has approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U).RAGWITEK is allergen extract indicated as immunotherapy for treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen.RAGWITEK is approved for use in adults 18 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms.Prescribing information for RAGWITEK includes a boxed warning regarding severe allergic reactions. 

Company Quote

48.47
-0.38 -0.78%
10:56am EST